BRPI1011540A2 - anticorpos anticxcr4 para o tratamento de of hiv - Google Patents
anticorpos anticxcr4 para o tratamento de of hivInfo
- Publication number
- BRPI1011540A2 BRPI1011540A2 BRPI1011540-4A BRPI1011540A BRPI1011540A2 BR PI1011540 A2 BRPI1011540 A2 BR PI1011540A2 BR PI1011540 A BRPI1011540 A BR PI1011540A BR PI1011540 A2 BRPI1011540 A2 BR PI1011540A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- hiv
- treatment
- anticxcr4
- cxcr4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"anticorpos anticxcr4 para o tratamento de of hiv". a presente invenção se refere a novos anticorpos isolados, ou 5 os compostos derivados ou fragmentos funcionais dos mesmos, capazes de se ligarem a cxcr4, mas também de induzir mudanças conformacionais dos homodímeros de cxcr4 e capazes de inibirem replicação isolada primária de hiv-1 em pbmc. mais particularmente, a presente invenção se refere aos anticorpos monoclonais 515h7 e 301 ae5, específicos para a pro- 10 teína cxcr4, bem como seu uso para o tratamento de infecção de hiv. composições farmacêuticas compostas de tais anticorpos e um processo para a seleção de tais anticorpos são também cobertos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17368009P | 2009-04-29 | 2009-04-29 | |
EP09159076.0 | 2009-04-29 | ||
EP09159076A EP2246364A1 (en) | 2009-04-29 | 2009-04-29 | Anti CXCR4 antibodies for the treatment of HIV |
US61/173,680 | 2009-04-29 | ||
PCT/EP2010/055863 WO2010125162A1 (en) | 2009-04-29 | 2010-04-29 | Anti cxcr4 antibodies for the treatment of hiv |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1011540A2 true BRPI1011540A2 (pt) | 2019-04-30 |
Family
ID=41060014
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1011540-4A BRPI1011540A2 (pt) | 2009-04-29 | 2010-04-29 | anticorpos anticxcr4 para o tratamento de of hiv |
BR112013009984A BR112013009984A2 (pt) | 2009-04-29 | 2011-10-27 | anticorpos para tratamento do hiv |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013009984A BR112013009984A2 (pt) | 2009-04-29 | 2011-10-27 | anticorpos para tratamento do hiv |
Country Status (26)
Country | Link |
---|---|
US (3) | US9090686B2 (pt) |
EP (2) | EP2246364A1 (pt) |
JP (1) | JP5800802B2 (pt) |
KR (1) | KR20120039525A (pt) |
CN (1) | CN102459343B (pt) |
AU (1) | AU2010243526B2 (pt) |
BR (2) | BRPI1011540A2 (pt) |
CA (1) | CA2759989A1 (pt) |
CL (1) | CL2011002664A1 (pt) |
CO (1) | CO6390114A2 (pt) |
ES (1) | ES2534313T3 (pt) |
GE (1) | GEP20146181B (pt) |
HK (1) | HK1165813A1 (pt) |
HU (1) | HUE025083T2 (pt) |
IL (1) | IL215919A0 (pt) |
MA (1) | MA33285B1 (pt) |
MX (1) | MX2011011285A (pt) |
MY (1) | MY155400A (pt) |
NZ (1) | NZ596712A (pt) |
PL (1) | PL2424897T3 (pt) |
RU (1) | RU2573902C2 (pt) |
SG (1) | SG175353A1 (pt) |
TN (1) | TN2011000534A1 (pt) |
UA (1) | UA107929C2 (pt) |
WO (1) | WO2010125162A1 (pt) |
ZA (1) | ZA201108330B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
JP2014504147A (ja) * | 2010-10-27 | 2014-02-20 | ピエール、ファーブル、メディカマン | Hivの治療用抗体 |
ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
CN106102837B (zh) | 2013-12-02 | 2020-10-13 | 艾伦戴蒙德艾滋病研究中心 | 双特异性hiv-1-中和抗体 |
US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
KR102165120B1 (ko) | 2015-12-15 | 2020-10-13 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스 중화 항체 |
KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3 |
US11180575B2 (en) | 2018-12-28 | 2021-11-23 | Corn Products Development, Inc. | Thermally inhibited starch and process for making |
WO2019191133A1 (en) | 2018-03-27 | 2019-10-03 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
CN111214650A (zh) * | 2018-11-23 | 2020-06-02 | 广州溯原生物科技有限公司 | 一种hiv抗原-受体三聚体复合物的解离因子的应用 |
WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
EP3973274A1 (en) | 2019-05-23 | 2022-03-30 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
KR20220129044A (ko) * | 2020-01-16 | 2022-09-22 | 카이로스 테라퓨틱스 인코포레이티드 | 골수종 및 난소암 세포에 특이적인 인간화 항체 |
JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル-マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
US12006353B2 (en) * | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
EP0512112B1 (en) * | 1990-11-27 | 1997-05-28 | Biogen, Inc. | Anti cd-4 antibodies blocking hiv-induced syncytia |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5844094A (en) * | 1992-09-25 | 1998-12-01 | Commonwealth Scientific And Industrial Research Organization | Target binding polypeptide |
AU1834197A (en) * | 1996-01-30 | 1997-08-22 | National Institutes Of Health, The | Cells expressing both human cd4 and cxcr4 |
WO2001042308A2 (en) * | 1999-12-08 | 2001-06-14 | Novartis Ag | Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1 |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
WO2005010153A2 (en) * | 2003-06-30 | 2005-02-03 | Bio-Technology General (Israel) Ltd. | Antibodies and uses thereof |
US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
BRPI0717512A2 (pt) * | 2006-09-29 | 2013-11-19 | Hoffmann La Roche | Anticorpos contra ccr5 e usos dos mesmos |
CN101951953A (zh) * | 2007-02-27 | 2011-01-19 | 株式会社未来创药研究所 | 含抗grp78抗体作为有效成分的药物组合物 |
EA201071300A1 (ru) * | 2008-05-14 | 2011-06-30 | Эли Лилли Энд Компани | Антитела к cxcr4 |
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
AU2010318542B2 (en) * | 2009-10-29 | 2015-08-27 | Janssen Biotech Inc. | Antibody glycosylation variants |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2009
- 2009-04-29 EP EP09159076A patent/EP2246364A1/en not_active Withdrawn
-
2010
- 2010-04-29 PL PL10721376T patent/PL2424897T3/pl unknown
- 2010-04-29 HU HUE10721376A patent/HUE025083T2/en unknown
- 2010-04-29 MA MA34368A patent/MA33285B1/fr unknown
- 2010-04-29 CA CA2759989A patent/CA2759989A1/en not_active Abandoned
- 2010-04-29 MY MYPI2011005123A patent/MY155400A/en unknown
- 2010-04-29 BR BRPI1011540-4A patent/BRPI1011540A2/pt not_active IP Right Cessation
- 2010-04-29 WO PCT/EP2010/055863 patent/WO2010125162A1/en active Application Filing
- 2010-04-29 EP EP10721376.1A patent/EP2424897B1/en active Active
- 2010-04-29 JP JP2012507772A patent/JP5800802B2/ja not_active Expired - Fee Related
- 2010-04-29 KR KR1020117027755A patent/KR20120039525A/ko not_active Application Discontinuation
- 2010-04-29 MX MX2011011285A patent/MX2011011285A/es active IP Right Grant
- 2010-04-29 NZ NZ596712A patent/NZ596712A/xx not_active IP Right Cessation
- 2010-04-29 ES ES10721376.1T patent/ES2534313T3/es active Active
- 2010-04-29 AU AU2010243526A patent/AU2010243526B2/en not_active Ceased
- 2010-04-29 UA UAA201114024A patent/UA107929C2/ru unknown
- 2010-04-29 CN CN201080028221.XA patent/CN102459343B/zh not_active Expired - Fee Related
- 2010-04-29 RU RU2011148077/10A patent/RU2573902C2/ru not_active IP Right Cessation
- 2010-04-29 GE GEAP201012429A patent/GEP20146181B/en unknown
- 2010-04-29 SG SG2011078334A patent/SG175353A1/en unknown
- 2010-10-27 US US12/913,300 patent/US9090686B2/en not_active Expired - Fee Related
-
2011
- 2011-10-21 TN TNP2011000534A patent/TN2011000534A1/en unknown
- 2011-10-25 IL IL215919A patent/IL215919A0/en unknown
- 2011-10-26 CL CL2011002664A patent/CL2011002664A1/es unknown
- 2011-10-27 US US13/823,182 patent/US20130174288A1/en not_active Abandoned
- 2011-10-27 BR BR112013009984A patent/BR112013009984A2/pt not_active IP Right Cessation
- 2011-11-14 ZA ZA2011/08330A patent/ZA201108330B/en unknown
- 2011-11-25 CO CO11162444A patent/CO6390114A2/es active IP Right Grant
-
2012
- 2012-07-04 HK HK12106487.3A patent/HK1165813A1/xx not_active IP Right Cessation
-
2015
- 2015-06-22 US US14/745,866 patent/US20160031995A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1011540A2 (pt) | anticorpos anticxcr4 para o tratamento de of hiv | |
BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
BR112015014751A8 (pt) | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. | |
BRPI0911273B8 (pt) | composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação | |
BRPI0720588B8 (pt) | derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase | |
BRPI0815134A2 (pt) | Processo para a preparação de olmesartana medoxomila | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
BRPI0613859A8 (pt) | compostos derivados de nitrocatecol, seu uso e seu processo de preparação, bem como composição farmacêutica | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
BRPI0514133A (pt) | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i | |
BRPI0817242A8 (pt) | compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm | |
CL2011002878A1 (es) | Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih. | |
BRPI1008145B8 (pt) | Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica | |
CL2009002206A1 (es) | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. | |
CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
BR112016006151A2 (pt) | imidazopiridazinas úteis como inibidores da via de sinalização do par-2 | |
BR112014009006B8 (pt) | Compostos heterocíclicos e métodos de uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |